<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315132</url>
  </required_header>
  <id_info>
    <org_study_id>08D.85</org_study_id>
    <secondary_id>2007-61</secondary_id>
    <nct_id>NCT01315132</nct_id>
  </id_info>
  <brief_title>A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies</brief_title>
  <official_title>A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in
      matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to
      increase overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research protocol has been developed for patients undergoing matched-sibling
      hematopoietic stem cell transplant (HSCT). The patients who are treated according to this 2
      step allogeneic HSCT protocol will receive cyclophosphamide to induce in-vivo tolerization of
      both autologous and allogeneic lymphocytes, followed by an allogeneic CD34-selected HSCT. The
      primary research questions relate to immune reconstitution, incidence of GVHD, and relapse in
      patients who receive lymphocyte treatment of this type in allogeneic HSCT and how it impacts
      overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2008</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">September 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Overall Survival</measure>
    <time_frame>1 Year after transplant</time_frame>
    <description>The primary objective of this prospective, phase II trial was to obtain an OS rate of &gt;60% at 1 year in patients undergoing a 2 step HSCT from an HLA compatible family donor. The &gt;60% threshold was selected as a composite efficacy measure as patients with any hematologic diagnosis, stage of disease, or age as old as 65 years were eligible for this treatment protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft Versus Host Disease (GVHD)</measure>
    <time_frame>1 Year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hodgkin's Disease</condition>
  <arm_group>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matched Sibling Allogeneic Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Matched Sibling Allogeneic Transplantation</intervention_name>
    <description>Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>CliniMACS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is
             thought to be beneficial, and in whom front-line therapy has already been applied.
             Patients will be considered high-risk if they have any of the following:

               1. Age &gt; 50 years

               2. ECOG Performance status of &lt;2

               3. Acute leukemia: requiring more than one chemotherapy regimen to obtain 1st CR;
                  second or greater CR, 1st relapse; any ph+ ALL

               4. CML 2nd chronic phase, accelerated phase, or blastic phase

               5. MDS with IPS of Intermediate 2 or greater

               6. Any myeloproliferative disorder

               7. Hodgkin lymphoma: relapsed, refractory, or primary induction failure

               8. Non-Hodgkin lymphoma: relapsed, refractory, primary treatment failure, or not
                  eligible for an autologous HSCT

               9. Other conditions not listed will be assessed as high-risk by the PI

          2. Patients must have a related donor who is either HLA-identical or a one antigen
             mismatch at the HLA- A; B; C; and DR loci.

          3. Patients must adequate organ function:

               1. LVEF of &gt;45%

               2. DLCO (adjusted for hemoglobin) &gt;45% of predicted

               3. Adequate liver function as defined by a serum bilirubin &lt;1.8, AST or ALT &lt; 2.5X
                  upper limit of normal

               4. Creatinine clearance of &gt; 60 ml/min

          4. Patients must be willing to use contraception if they have childbearing potential

          5. Able to give informed consent

        Exclusion Criteria:

          1. ECOG performance status of 3 or 4.

          2. HIV positive

          3. Active involvement of the central nervous system with malignancy

          4. Psychiatric disorder that would preclude patients from signing an informed consent

          5. Pregnancy

          6. Patients with life expectancy of &lt; 6 months for reasons other than their underlying
             hematologic/oncologic disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Flomenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <results_first_submitted>September 4, 2019</results_first_submitted>
  <results_first_submitted_qc>September 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 15, 2019</results_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloablative Hematopoietic Stem Cell Transplant</keyword>
  <keyword>Cyclophosphamide tolerization</keyword>
  <keyword>2 Step Approach</keyword>
  <keyword>Hematological malignancies</keyword>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT01315132/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic Transplantation</title>
          <description>Matched Sibling Allogeneic Transplantation
Matched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not treated due to disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>While 47 participants were enrolled, one participant was removed from the study prior to treatment and will not be counted in the outcomes of the trial</population>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic Transplantation</title>
          <description>Matched Sibling Allogeneic Transplantation
Matched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Overall Survival</title>
        <description>The primary objective of this prospective, phase II trial was to obtain an OS rate of &gt;60% at 1 year in patients undergoing a 2 step HSCT from an HLA compatible family donor. The &gt;60% threshold was selected as a composite efficacy measure as patients with any hematologic diagnosis, stage of disease, or age as old as 65 years were eligible for this treatment protocol.</description>
        <time_frame>1 Year after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Matched Sibling Allogeneic Transplantation
Matched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Overall Survival</title>
          <description>The primary objective of this prospective, phase II trial was to obtain an OS rate of &gt;60% at 1 year in patients undergoing a 2 step HSCT from an HLA compatible family donor. The &gt;60% threshold was selected as a composite efficacy measure as patients with any hematologic diagnosis, stage of disease, or age as old as 65 years were eligible for this treatment protocol.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Versus Host Disease (GVHD)</title>
        <time_frame>1 Year after transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Matched Sibling Allogeneic Transplantation
Matched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Versus Host Disease (GVHD)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Acute GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No GVHD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from baseline through one year after transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic Transplantation</title>
          <description>Matched Sibling Allogeneic Transplantation
Matched Sibling Allogeneic Transplantation: Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="35" subjects_affected="30" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neal Flomenberg, MD</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215-955-4367</phone>
      <email>Neal.Flomenberg@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

